Our heritage in neuroscience began in the late 1950s when Dr. Paul Janssen developed a drug that revolutionized the standard of care for schizophrenia.
Since then, our medications and innovations have improved quality of care for millions of patients living with neuropsychiatric conditions around the world. In fact, three of our medicines have been on the World Health Organization’s Essential Medicines List.
Despite progress in understanding and treating these conditions, significant unmet needs persist. For example, under current standard-of-care, seven out of ten patients with major depressive disorder (MDD) experience residual symptoms.
Today, we are committed to developing precision therapies that specifically target the underlying mechanism of MDD and address these inadequately treated symptoms.